Zosuquidar (LY335979) 3HCl: A Potent P-glycoprotein Modulator for Reversing Multidrug Resistance in Cancer

Executive Summary: Zosuquidar (LY335979) 3HCl is a highly selective inhibitor of P-glycoprotein (P-gp), an ATP-dependent efflux pump implicated in multidrug resistance (MDR) across various cancers (APExBIO). In vitro, Zosuquidar restores tumor cell sensitivity to chemotherapeutics such as vinblastine and doxorubicin at low micromolar concentrations. Animal studies confirm Zosuquidar enhances antitumor efficacy and survival without altering drug pharmacokinetics (Sun et al., 2025). Clinical trials report effective P-gp inhibition and minimal added toxicity when combined with standard regimens. The compound offers reliable solubility in DMSO, with robust storage guidance for consistent laboratory use. These properties make Zosuquidar a benchmark tool for MDR research and translational oncology workflows.

Biological Rationale

P-glycoprotein (P-gp, ABCB1) is a transmembrane efflux transporter expressed in tissues including brain, liver, small intestine, and tumor cells. It uses ATP hydrolysis to pump xenobiotics and chemotherapeutics out of cells, reducing intracellular drug accumulation and efficacy (Sun et al., 2025). P-gp overexpression is a principal cause of multidrug resistance (MDR) in cancers such as acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (Reversing Cancer Multidrug Resistance). Modulating P-gp function is essential for restoring chemotherapy sensitivity and improving clinical outcomes.

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar (LY335979) 3HCl acts as a competitive inhibitor of P-gp. It binds to the transporter’s substrate recognition site, preventing efflux of chemotherapeutic agents such as vinblastine, doxorubicin, etoposide, and paclitaxel (Zosuquidar: Next-Generation P-gp Inhibition). This blockade increases the intracellular concentration of cytotoxic drugs in resistant tumor cells, reversing the MDR phenotype. Zosuquidar does not significantly inhibit other ATP-binding cassette (ABC) transporters at low micromolar doses, supporting its selectivity. Its chemical structure ((2R)-1-(4-((1aR,10bS)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl)piperazin-1-yl)-3-(quinolin-5-yloxy)propan-2-ol) confers high affinity for P-gp. The product (SKU A3956) is available from APExBIO with a molecular weight of 527.6 and CAS number 167354-41-8 (product page).

Evidence & Benchmarks

• In vitro, Zosuquidar restores sensitivity to vinblastine, doxorubicin, etoposide, and paclitaxel in P-gp overexpressing leukemia and solid tumor cell lines at concentrations as low as 0.1–2 μM (Sun et al., 2025).
• In vivo murine models show enhanced antitumor efficacy and increased survival when Zosuquidar is combined with chemotherapeutics, without altering systemic drug pharmacokinetics (Sun et al., 2025).
• Phase I/II clinical trials report effective P-gp inhibition and minimal additional toxicity when Zosuquidar is used with CHOP regimens for non-Hodgkin's lymphoma and vinorelbine in advanced solid tumors (APExBIO).
• Pharmacokinetic studies confirm Zosuquidar’s action is specific to P-gp, with negligible effect on CYP450-mediated metabolism at experimental concentrations (Sun et al., 2025).
• Compared to earlier P-gp inhibitors, Zosuquidar demonstrates greater selectivity and lower off-target toxicity (Mechanistic Mastery and Strategy).

Applications, Limits & Misconceptions

Zosuquidar is widely used as a research reagent to study P-glycoprotein function and to model MDR reversal in preclinical cancer models. Its selectivity makes it a preferred tool for dissecting P-gp-mediated drug resistance. However, Zosuquidar is not effective against resistance mediated by non-P-gp transporters or mutation-driven drug insensitivity. In the clinical setting, its use is primarily investigational, and its role as a routine adjuvant remains under study (Reliable P-gp Inhibition).

Common Pitfalls or Misconceptions

• Zosuquidar does not reverse resistance mediated by other ABC transporters such as MRP1 or BCRP.
• It should not be stored as a solution for long-term use; stability is optimal in solid form at −20°C (APExBIO).
• Zosuquidar is not a cytotoxic agent and does not induce cell death on its own.
• Clinical efficacy depends on co-administration with P-gp substrate chemotherapeutics; solo administration is ineffective for overcoming MDR.
• Solubility is high in DMSO but may be limited in aqueous buffers without co-solvents.

Workflow Integration & Parameters

For in vitro assays, Zosuquidar (LY335979) 3HCl is typically applied at 0.1–2 μM in DMSO, with a final solvent concentration ≤0.1% (v/v) to avoid cytotoxicity. In vivo, dosing regimens range from 5–25 mg/kg, administered orally or intravenously, depending on the model (Sun et al., 2025). The A3956 kit from APExBIO provides standardized material for reproducibility. Researchers are advised not to store working solutions for extended periods due to stability concerns. APExBIO supplies detailed protocols and batch-specific data to support experimental design (product page).

This article extends the mechanistic and translational focus of "Reversing Cancer Multidrug Resistance" by providing updated clinical benchmarks and workflow guidelines. Additionally, it clarifies distinctions drawn in "Zosuquidar: Next-Generation P-gp Inhibition" by emphasizing selective action and storage protocols.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is a validated, selective P-glycoprotein inhibitor that reverses MDR in preclinical cancer models and enhances chemotherapy efficacy in early clinical trials. The specificity, low toxicity, and robust performance of APExBIO's formulation (SKU A3956) support its use in advanced MDR research and translational workflows. Ongoing clinical investigations will clarify its full therapeutic potential and optimal integration with chemotherapeutic regimens. For further details and ordering information, visit the APExBIO Zosuquidar (LY335979) 3HCl product page.